Phase 2 N=71 Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
Optic Neuritis
Primary: Retinal Ganglion Cell Inner Plexiform Layer Thickness — 36.56; 34.65; 31; 29.42 micron
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=40 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)
Hypertension
Primary: Participants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE) During Treatment and Postdose Follow-up — 5; 0; 5; 1 Count of Participants
Phase 3 N=542 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)
Phase 4 N=63 Preoperative Gabapentin Versus Bisoprolol for Hemodynamic Optimization During Sinus Surgery
Blood Pressure
Primary: Changes in Surgical Field Visibility — 2; 2; 4; 1 score on a scale
N/A N=40 Assessment of the Acute Effect of Cycling Practice in Lumbar and Thigh Muscles
Physical Endurance · Muscle Fatigue · Musculoskeletal Pain
Primary: Low Back Pain Perception (LBPP) — 1; 0.8; 3.4; 3.3 units on a scale
N/A N=9 Neural Prostheses and Gait Performance: Model-Based Strategies
Hemiplegia
Primary: Walking Stability and Speed — 0.1055; 0.0390; 0.0206 Joules/body mass in kilograms
Phase 2 N=88 Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
Alzheimer's Disease
Primary: Changes in Cerebrospinal Fluid (CSF) Beta-amyloid-42 Levels Compared to Baseline as Measured by xMAP — 1.01; 0.98 ratio
Phase 1 N=16 Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers
Renal Function Impairment in Healthy Volunteers
Primary: Renal Plasma Flow — 541; 663 mL/min — p=< 0.0001
Phase 4 N=776 A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 — 0.092; 0.059 Liters — p=0.051
Phase 2 N=24 Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System
Cardiovascular Diseases · Coronary Artery Disease
Primary: Number of Treatment-related Adverse Events — 6 Adverse events
N/A N=24 Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients
Hidradenitis Suppurativa
Primary: Change From Baseline in DLQI at Week 12 — -7.8 score on a scale — p=0.0001
N/A N=312 Pertussis Infection in Adolescents and Adults With Prolonged Cough
Pertussis
Primary: Serological Evidence of Pertussis Infection — 50; 74; 84; 26 Participants
N/A N=42 Laser Ablation After Stereotactic Radiosurgery
Metastatic Brain Tumors · Progression · Radiation Necrosis
Primary: Percentage of Patients With Progression-Free Survival (PFS) — 74; 74 percentage of patients
Phase 2 N=131 A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)
Muscular Atrophy, Spinal
Primary: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) — 27.5; 91.6 percentage of participants
Phase 2 N=66 c-Met Second-Line Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…